Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases

PURPOSE: Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Löb, Sanja, Linsmeier, Eva, Herbert, Saskia-Laureen, Schlaiß, Tanja, Kiesel, Matthias, Wischhusen, Jörg, Salmen, Jessica, Kranke, Peter, Quenzer, Anne, Kurz, Florian, Weiss, Claire, Gerhard-Hartmann, Elena, Wöckel, Achim, Diessner, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349762/
https://www.ncbi.nlm.nih.gov/pubmed/36451043
http://dx.doi.org/10.1007/s00432-022-04486-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349762/
https://www.ncbi.nlm.nih.gov/pubmed/36451043
http://dx.doi.org/10.1007/s00432-022-04486-0

Ejemplares similares